Bay Area Biotech on 12/6 →
Founder, Young Inventors
Nobel Laureate, Professor of Biology, Caltech
Founder and Managing Director of DEV
CEO of Zero Locus
Co-Founder and CEO, DNAnexus
Chairman, CEO, & Founder, Alexandria Real Estate Equities
December 5, 2017 ·
December 6, 2017 ·
December 11, 2017 ·
(Page 14 of 18)
Wade Roush is the producer and host of the podcast Soonish and a contributing editor at Xconomy. Follow @soonishpodcast
It’s too bad there’s a glut of consumer mHealth out there right now, same can be said for CES. We have a ton of “me too’s” so again the incubator folks would do well to incubate with themselves and create apps that do more than one thing. Problem is that the consumer is very slow to adapt and see value as everything wants the consumer to give time but little value has been proven yet.
Now if you want value and a vehicle, get those bar codes out on FDA recalls and they you would see more of a consumer interest. I have been blogging about this same topic for a few years and wrote an EMR a few years ago myself and it’s the same old stuff and marketing today really puts a spin on it with math no longer being 100% methodology for measuring accuracy.
It’s all about more algorithms to sell more software which in itself i not bad but so much glut and lack of consumer participation and we don’t have any role models either. I can’t even find so much as a picture of HHS Sebeluis on the web with as much as a cell phone in her hand:) Bar codes for FDA recalls would have value and engage consumers and in addition we all worry about who gathers and sells data.
Actually every time a buy a tire for my car I think about the billions made with selling data as Walgreens said their data selling business is worth just under $800 million, data they get for free and some states have had to install software to keep the data mining bots out as the servers slow down to a crawl and consumers can’t get in and this is what it was set up for.
Most consumer apps today are built around advertising and selling data too so I say license and tax those folks, like a sales tax for what they get to sell “free taxpayer data” they mine. It will all choke out one day here.
So again based on these side effects I too don’t have a lot of interest as I know when I read the fine print it’s all about making money selling algorithms, whether the data is correct or flawed. There’s plenty of good but with the current economy today, it’s the Attack of the Killer Algorithms to watch for with flawed data and hopefully our new Consumer Financial Chief will have a “tiny” bit of IT in his background. If not, we are screwed as corporate US knows how work it and with machine learning data we are somewhat writing the unreadable too, words credited from Kevin Slavin.
Sponsored · Whitepaper
Reduce turnaround times, cut excessive admin expenses and increas
The business landscape is constantly evolving. Why shouldn’t your company change with it?
The pressure has never been greater for life science organizations to shorten the development cycle for new drugs and devices.
The state’s programs for entrepreneurs made a record-setting impact in 2016.
Xconomy offers a number of ways to subscribe for free!
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin, Indiana, and beyond.
© 2007-2017, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Website development support from Andrew Koyfman with design support from Rob Hunter.